Clinical Trials on Pulmonary Hypoplasia in New Zealand

Total 1144 results

AstraZeneca

Completed

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Ministry of Science and Technology, India

Completed

Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.

Tuberculosis

India
Inari Medical

Completed

FlowTriever Pulmonary Embolectomy Clinical Study (FLARE)

Pulmonary Embolism | Submassive Pulmonary Embolism | Acute Pulmonary Embolism | Massive Pulmonary Embolism

United States
United Therapeutics

Completed

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Pulmonary Hypertension | Interstitial Lung Disease | Combined Pulmonary Fibrosis and Emphysema

United States, Puerto Rico
AstraZeneca

Completed

Exacerbations and Their Outcomes International (EXACOS International) (EXACOS-Intl)

Chronic Obstructive Pulmonary Disease

Taiwan, Russian Federation, Mexico, Chile
Laval University
Canadian Institutes of Health Research (CIHR)

Completed

The International Nocturnal Oxygen (INOX) Trial (INOX)

Chronic Obstructive Pulmonary Disease | Nocturnal Desaturation

Spain, Canada, France, Portugal
Johns Hopkins University
Medtronic

Completed

Pulmonary Artery Repair With Covered Stents (PARCS)

Tetralogy of Fallot | Pulmonary Regurgitation | Pulmonary Stenosis

United States
Actelion

Completed

Iloprost Power 15 in Pulmonary Arterial Hypertension (PROWESS 15)

Pulmonary Arterial Hypertension

United States, Austria, Germany
United Therapeutics
Lung Biotechnology PBC

Completed

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH (PRN)

Pulmonary Arterial Hypertension

United States
GlaxoSmithKline

Completed

Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With COPD (PACE)

Pulmonary Disease, Chronic Obstructive

Taiwan, Korea, Republic of, China, Australia
Actelion

Completed

Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension (PROWESS 15 Ext)

Pulmonary Arterial Hypertension

United States, Germany, Austria
United Therapeutics

Completed

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
University of Minnesota
National Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health... and other collaborators

Terminated

Simvastatin Therapy for Moderate and Severe COPD (STATCOPE)

Pulmonary Disease, Chronic Obstructive

United States, Canada
Pearl Therapeutics, Inc.

Completed

PT003 MDI Dose Confirmation Study

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD. (MOVE)

Chronic Obstructive Pulmonary Disease

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer (LEVER)

Atypical Endometrial Hyperplasia | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

United States
LungLife AI

Recruiting

LungLB in Subjects Presenting With Indeterminate Pulmonary Nodules

Multiple Pulmonary Nodules | Solitary Pulmonary Nodule

United States
Spruce Biosciences

Recruiting

A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children With CAH

Congenital Adrenal Hyperplasia | 21-OHD

United States
Apreo Health, Inc.

Recruiting

First in Human Study to Assess an Implant to Treat Severe Emphysema (BREATHE-1)

Emphysema or COPD

Australia
Bayer
Xcenda, LLC

Active, not recruiting

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) (ROAR)

Pulmonary Arterial Hypertension

United States, Puerto Rico
Duke University
National Heart, Lung, and Blood Institute (NHLBI); Duke Clinical Research Institute

Terminated

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF)

Idiopathic Pulmonary Fibrosis

United States
Novartis Pharmaceuticals

Completed

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Taiwan, Korea, Republic of, Japan, India, Hong Kong, Singapore
Pfizer

Terminated

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension (STRIDE-3)

Pulmonary Arterial Hypertension

United States, Netherlands, Canada, Belgium, France, Germany, Italy, Spain, United Kingdom, Australia, Poland, Austria, Brazil, Israel, Argentina, Mexico
Boehringer Ingelheim

Completed

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

Pulmonary Disease, Chronic Obstructive

United States, Germany
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) (PULSAR)

Pulmonary Arterial Hypertension

Spain, United States, Israel, Australia, Germany, United Kingdom, France, Brazil
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Hoffmann-La Roche

Recruiting

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ARNASA)

Chronic Obstructive Pulmonary Disease (COPD)

United States, China, Spain, Italy, Germany, Belgium, Korea, Republic of, Poland, Taiwan, Israel, New Zealand, Sweden, United Kingdom, Japan, Czechia, Philippines, Hong Kong, Greece, Australia, Thailand, Netherlands, Argentina, Brazil, Fran... and more
Incyphae, Inc.

Completed

SNORE (Smartphone Analyses of Nocturnal Obstruction by Respiratory Evaluation) SOUNDS (SNORESOUNDS)

Sleep Apnea, Obstructive | Chronic Obstructive Pulmonary Disease

United States
AstraZeneca
Amgen

Completed

Tezepelumab COPD Exacerbation Study (COURSE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Canada, Denmark, France, United Kingdom, Korea, Republic of, Germany, Israel, Spain, Netherlands
Pfizer

Terminated

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

Pulmonary Arterial Hypertension | Pulmonary Hypertension

United States, Bulgaria, Argentina, Chile, China, Colombia, Costa Rica, Czech Republic, Dominican Republic, Guatemala, India, Malaysia, Mexico, Peru, Philippines, Romania, Russian Federation, Saudi Arabia, Serbia, Slovakia, South... and more
University of Alabama at Birmingham
University of Michigan; Tulane University; Temple University

Recruiting

GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis (GKT137831)

Idiopathic Pulmonary Fibrosis

United States
AstraZeneca

Completed

Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)

Chronic Obstructive Pulmonary Disease | COPD

United States, Argentina, Canada, Colombia, Mexico, Peru
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
Vectura, Inc.
Syneos Health

Terminated

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

Obstructive Pulmonary Function | Restrictive Pulmonary Function

United States
Ochsner Health System
Gilead Sciences

Withdrawn

Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

Pulmonary Hypertension | Cirrhosis, Liver | Portopulmonary Hypertension

United States
GlaxoSmithKline

Completed

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease (ESWT)

Pulmonary Disease, Chronic Obstructive

Canada, United States
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Completed

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

Pulmonary Arterial Hypertension

United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Serbia, Spain, Sweden, Switzerland, United Kingdom
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, Netherlands, Czechia
Actelion

Completed

Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension | Pulmonary Hypertension | Ayerza Syndrome

United States
United Therapeutics

Completed

A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension

Pulmonary Hypertension

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) (INSIST)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Germany, Spain, Turkey, Hungary, Czech Republic, India, Slovakia
AstraZeneca

Completed

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Chronic Obstructive Pulmonary Disease COPD

United States, Netherlands, Argentina, South Africa, Chile, Peru
GlaxoSmithKline

Completed

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Estonia, Canada, Chile, Germany, Peru, Philippines, Mexico, Korea, Republic of, Denmark, Russian Federation, Poland, Slovakia
Hoffmann-La Roche

Completed

A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (ISLAND2)

Idiopathic Pulmonary Fibrosis

United States, Germany
Heidelberg University

Terminated

Correlation of FeNO, Blood Eosinophils, Bronchoalveolar Lavage Findings and Bronchial Epithelium Histopathology in Patients With Chronic Obstructive Pulmonary Disease and Asthma

Obstructive Lung Diseases

Australia, Germany
Fu Jen Catholic University

Completed

The Application and Analysis of HHHFNC in Walking Test of Pulmonary Rehabilitation

Rehabilitation | Pulmonary Disease | COPD

Taiwan
GlaxoSmithKline

Completed

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Russian Federation, Spain, Bulgaria, Canada, Hungary, Argentina
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

Chronic Obstructive Pulmonary Disease

United States, Czech Republic, Poland, South Africa, Netherlands
Institut für Pneumologie Hagen Ambrock eV
Fisher and Paykel Healthcare

Completed

Efficacy and Physiology of Nasal High Flow Therapy

Pulmonary Disease, Chronic Obstructive

Germany
United Therapeutics
Lung Biotechnology PBC

Terminated

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD) (PERFECT OLE)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Israel

Clinical Trials on Pulmonary Hypoplasia in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations